Severe fingolimod rebound syndrome after switching to cladribine treatment-Reference-Cited by-同舟云学术

Severe fingolimod rebound syndrome after switching to cladribine treatment

Published:2020-05 Issue: Volume:40 Page:101938
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Coss-Rovirosa Fernanda,Salado-Burbano Jorge,Casallas-Vanegas Adriana^ORCID,Caire-Herrera Laura Elizabeth,Gómez-Figueroa Enrique^ORCID,Flores-Rivera José^ORCID

Publisher

Elsevier BV

Subject

Clinical Neurology,Neurology,General Medicine

Reference15 articles.

1. Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis;Alvarez-Gonzalez;Ann. Clin. Transl. Neurol.,2017

2. Tumefactive rebound of multiple sclerosis after the short-term cessation of fingolimod: a case report;Ashtari;Mult. Scler. Relat. Disord.,2019

3. Fingolimod rebound: a review of the clinical experience and management considerations;Barry;Neurol. Ther.,2019

4. Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation;Berger;J. Neuroimmunol.,2015

5. Compositional changes of B and T cell subtypes during fingolimod treatment in multiple sclerosis patients: a 12-month follow-up study;Claes;PLoS ONE,2014

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Switching to ozanimod as a strategy to adjust fingolimod-related lymphopenia;Multiple Sclerosis and Related Disorders;2024-01

2. Treatment algorithms of relapsing multiple sclerosis: an exploration based on the available disease-modifying therapies in China;Therapeutic Advances in Neurological Disorders;2024-01

3. Real-World Effectiveness of Cladribine for Patients with Multiple Sclerosis: A Sicilian Multicentric Experience (Rewind Study);Current Neuropharmacology;2024-01

4. Prediction of relapse activity when switching to cladribine for multiple sclerosis;Multiple Sclerosis Journal;2022-07-27

5. Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis;Multiple Sclerosis and Related Disorders;2022-06